Plain-English translation of NCT06284122 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a new treatment called combined with works better and is safer than standard chemotherapy treatments for follicular lymphoma that has never been treated before. About 790 people will be randomly assigned to receive either the new medication combination or one of several standard chemotherapy regimens. The study will track how well each treatment works and what side effects participants experience over about 2.5 years of active treatment.
Follicular lymphoma is a slow-growing blood cancer, and while standard chemotherapy treatments have helped many patients, doctors are looking for options that may work better or cause fewer side effects. This trial is testing whether this new medication combination could become a better first-line treatment choice.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will first go through a screening phase lasting up to 6 weeks, during which doctors will confirm your diagnosis and check that you are healthy enough for the study. Then you will be randomly assigned to receive either the new medication combination or one of the standard chemotherapy options. Your treatment will last about 2.5 years total, with an initial intensive phase (about 11 months) followed by a maintenance phase (about 17 months). You will have regular clinic visits for blood tests, scans, and check-ups to monitor how well the treatment is working and manage any side effects. After active treatment ends, you will have follow-up visits for at least 3 months, and researchers will continue tracking your health for up to 7 years.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
Austria